Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02892123
Title Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Zymeworks Inc.
Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
University of Alabama Birmingham Alabama 35294 United States Details
USC/Norris Cancer Center Los Angeles California 90033 United States Details
Hoag Family Cancer Institute Newport Beach California 92663 United States Details
University of Colorado Cancer Center Aurora Colorado 80045 United States Details
Rush University Medical Center Chicago Illinois 60612 United States Details
Sarah Cannon - Tennessee Oncology Nashville Tennessee 37203 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
South Texas Accelerated Research Therapeutics (START) San Antonio Texas 78229 United States Details
Northwest Medical Specialties Tacoma Washington 98405 United States Details
University of Ottawa Ottawa Ontario K1H 8L6 Canada Details
Princess Margaret Cancer Centre Toronto Ontario M5G 2M9 Canada Details
Jewish General Hospital Montréal Quebec H3T1E2 Canada Details
Seoul National University Bundang Hospital Seongnam-si Gyeonggi-do 13620 Korea, Republic of Details
Seoul National University Hospital Seoul 03080 Korea, Republic of Details
Severance Hospital Seoul 03722 Korea, Republic of Details
Asan Medical Center Seoul 05505 Korea, Republic of Details
Samsung Medical Center Seoul 06351 Korea, Republic of Details
*Shaded cells indicate that there was no data available from for the field